Disease · MONDO_0005206

renal carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. renal carcinoma. Diseases, record MONDO_0005206. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005206

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: renal carcinoma; Open Targets
Open Targets ID: MONDO_0005206; Open Targets
Other names: carcinoma of kidney, kidney (including renal cell) cancer, kidney (renal) cancer, kidney cancer, kidney carcinoma, renal cancer; Open Targets
Disease Ontology: DOID:4451; Disease Ontology
NCI Thesaurus: C9384; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 39 drugs, from DailyMed; Open Targets

Drugs39

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MEDROXYPROGESTERONE ACETATE	CHEMBL717	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
ALDESLEUKIN	CHEMBL1201438	Protein	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
INTERFERON ALFA	CHEMBL2108506	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
IPILIMUMAB	CHEMBL1789844	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
PANITUMUMAB	CHEMBL1201827	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
SUNITINIB	CHEMBL535	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
AXITINIB	CHEMBL1289926	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CABOZANTINIB	CHEMBL2105717	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 39

See all 39 drugs

Targets123

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	6	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
PDCD1	Programmed cell death protein 1	4	Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
CSF1R	Macrophage colony-stimulating factor 1 receptor	2	Macrophage colony stimulating factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/1436	Drugs and targets
EGFR	Epidermal growth factor receptor	2	Epidermal growth factor receptor erbB1 inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	2	FK506-binding protein 1A inhibitor	Phase 2	https://conductscience.org/library/genes/2280	Drugs and targets
GABRA1	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Unknown	https://conductscience.org/library/genes/2556	Drugs and targets

1 to 10 of 123

See all 123 targets

Trials38

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00940498	Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors	Phase 1	78	2018-11-02	Neoplasms	GEDATOLISIB	Its record names the disease	ClinicalTrials.gov
NCT03239145	Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor	Phase 1	62	2026-03-12	Advanced Solid Tumor	PEMBROLIZUMAB, TREBANANIB	Its record names the disease	ClinicalTrials.gov
NCT00069160	Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer	Phase 2	48	2012-10-12	Lung Neoplasms, Ovarian Neoplasms, Cervix Neoplasms, Renal Neoplasms	DOCETAXEL, TARIQUIDAR	Its record names the disease	ClinicalTrials.gov
NCT03296137	Adoptive Cell Therapy Across Cancer Diagnoses	Phase 1/2	25	2024-10-26	Cancer	ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE, IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT00089778	Vaccine Treatment of Kidney Cancer	Phase 2	11	2012-10-11	Kidney Cancer	ALDESLEUKIN	Its record names the disease	ClinicalTrials.gov
NCT01650350	Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer	Phase 2	7	2015-07-27	Melanoma, Prostate Cancer, Renal Cancer	NALTREXONE	Its record names the disease	ClinicalTrials.gov
NCT02859415	Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases	Phase 1/2	3	2022-04-05	Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymus Neoplasms, Neoplasms, Germ Cell and Embryonal	PLICAMYCIN	Its record names the disease	ClinicalTrials.gov
NCT02660411	Impact of Anesthesia Maintenance Methods on Long-term Survival	Not applicable	1,228		Aged, Neoplasms, Surgical Procedure, Operative, Anesthesia, Inhalation, Anesthesia, Intravenous, Survival	PROPOFOL, SEVOFLURANE	Its record names the disease	ClinicalTrials.gov
NCT05343260	Impact of Anesthesia Maintenance Methods on 5-year Survival After Surgery	Not applicable	1,228		Aged, Neoplasms, Surgical Procedure, Operative, Anesthesia, Inhalation, Anesthesia, Intravenous, Survival	PROPOFOL, SEVOFLURANE	Its record names the disease	ClinicalTrials.gov
NCT00291369	Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis	Phase 3	456		Metastatic Renal Cell Carcinoma	ALDESLEUKIN, INTERFERON ALFA, MEDROXYPROGESTERONE ACETATE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 38

See all 38 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Patients on Docetaxel on Days 1, 8 & Tariquidar on Day 8, 22 vs Patients on Docetaxel on Days 1, 8 & Tariquidar on Days 1, 22: The Number of Participants With Adverse Events.	23 of 23	25 of 25	48	NCT00069160	Trial comparisons
Patients on Docetaxel on Days 1, 8 & Tariquidar on Day 8, 22 vs Patients on Docetaxel on Days 1, 8 & Tariquidar on Days 1, 22: serious adverse events	6 of 23	8 of 25	48	NCT00069160	Trial comparisons
[Dose Escalation Dose Level I] Pembrolizumab + Trebananib vs [Dose Escalation Dose Level II] Pembrolizumab + Trebananib: Number of Participants Experienced Dose Limit Toxicities (DLT)	0 of 3	0 of 3	6	NCT03239145	Trial comparisons
Phase I Dose Level 1 Mithramycin 60 mcg/kg vs Phase I Dose Level -1 Mithramycin 60 mcg/kg Followed by Mithramycin 30 mcg/kg: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)	1 of 1	2 of 2	3	NCT02859415	Trial comparisons
Phase I Dose Level 1 Mithramycin 60 mcg/kg vs Phase I Dose Level -1 Mithramycin 60 mcg/kg Followed by Mithramycin 30 mcg/kg: deaths from any cause	0 of 1	0 of 2	3	NCT02859415	Trial comparisons
Phase I Dose Level 1 Mithramycin 60 mcg/kg vs Phase I Dose Level -1 Mithramycin 60 mcg/kg Followed by Mithramycin 30 mcg/kg: Number of Participants With a Dose-limiting Toxicity (DLT)	0 of 1	0 of 2	3	NCT02859415	Trial comparisons
Phase I Dose Level 1 Mithramycin 60 mcg/kg vs Phase I Dose Level -1 Mithramycin 60 mcg/kg Followed by Mithramycin 30 mcg/kg: serious adverse events	0 of 1	2 of 2	3	NCT02859415	Trial comparisons

Papers from its trials18

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
21081657	RESULT	1	PubMed
19010868	RESULT	1	PubMed
18794104	RESULT	1	PubMed
15210739	RESULT	1	PubMed
42313189	DERIVED	1	PubMed
38954871	DERIVED	1	PubMed
37474242	DERIVED	1	PubMed
35298698	DERIVED	1	PubMed
34607899	DERIVED	1	PubMed
32527643	DERIVED	1	PubMed

1 to 10 of 18

See all 18 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005206

GET https://conductscience.org/api/diseases/v1/MONDO_0005206/drugs?page=2

API reference For AI assistants